BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
Astra’s Claudin reckoning approaches
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
